Navigation Links
Vestara Announces Strategic Agreement with Leading Contract Services Company Novation
Date:8/26/2009

Vestara announced today a strategic agreement with leading contract services company Novation, to provide the nearly 2,000 VHA and University HealthSystem Consortium (UHC) and nearly 14,000 members of Provista, LLC with the only automated pharmaceutical waste management solution in the industry. Novation's vast network includes acute hospitals and systems, academic medical centers, ambulatory care and physician clinics, home health and long-term care facilities.

Irvine, CA (PRWEB) August 26, 2009 -- Vestara announced today a strategic agreement with leading contract services company Novation, to provide the nearly 2,000 VHA and University HealthSystem Consortium (UHC) and nearly 14,000 members of Provista, LLC with the only automated pharmaceutical waste management solution in the industry. Novation's vast network includes acute hospitals and systems, academic medical centers, ambulatory care and physician clinics, home health and long-term care facilities.

This strategic agreement presents the members with a make-sense solution for pharmaceutical waste management that controls costs and facilitates environmental responsibility. Vestara and Novation both strive to provide the healthcare industry with effective solutions that not only make economic sense for their clients, but that also contribute to preserving the environment.

Vestara's EcoRex® Automated Pharmaceutical Waste Management System utilizes barcode technology already widely used in hospitals to track drug utilization that prevents medication errors and a proprietary, continuously updated database of more than 180,000 National Drug Code (NDC) products, to instantly categorize pharmaceutical waste at time of presenta
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
2. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
3. Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009
4. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
5. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
6. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
7. Immucor Announces 2 Million Share Increase to Stock Repurchase Program
8. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
10. Cord Blood America Announces Preferred Pricing for Blue Cross of Northeastern Pennsylvania Members
11. Imagenetix, Inc. Announces Interview With Bloomberg Radio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical ... today,announced that Douglas B. Muchmore, MD, has joined ... "I am thrilled to welcome an individual of ... leadership team. He is a widely respected,endocrinologist for ...
... IRVINE, Calif., Sept. 23 Endocare, Inc.,(Nasdaq: ... on the,development of minimally invasive technologies for tissue ... Association (AUA),has for the first time posted on ... cryoablation for prostate cancer, covering,primary, salvage and focal ...
... SAN FRANCISCO, Calif., Sept. 23 ,Monogram Biosciences, Inc. ... has,initiated a study, in collaboration with the Dana-Farber ... Assay in,metastatic breast cancer., In the study, ... approximately 600 tissue samples from patients with breast ...
Cached Biology Technology:Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 2Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 4Best Practices Document on Cryoablation Posted on Website of American Urological Association 2Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 2Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 3Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 4
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... international collaborators have discovered the key to overcoming three ... growers worldwide in excess of AUS$7.8 billion. In ... Science , scientists from CSIRO Plant Industry, the University ... Center have identified a wheat gene sequence which provides ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
... Princeton, NJ February 23, 2009 - A new ... the Intergovernmental Panel on Climate Change (IPCC) 2001 Third ... increase in average global temperatures due to greenhouse gas ... of global concern. The study, published in the ...
Cached Biology News:Saving wheat crops worldwide 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 3
... a K-12 strain ideally suited as an ... transformation efficiency, blue/white screening capability (with appropriate ... in high yields of excellent quality plasmid ... potentially useful as a stringent host due ...
... Zealand White or Californian 8 - 10 ... 6 hours of collection, processed within 24 ... is then thawed in a cool waterbath, ... through a 0.22 micron filter, bottled, and ...
... Host Strain Competent Cell Sets Sets ... strain combinations The most common ... E. coli is to use chemically ... prepared in the laboratory, greater efficiency, reproducibility ...
... Imager delivers high resolution CCD confocal imaging ... effective optical package that fits on your ... combined with high quantum efficiency CCD cameras, ... recording at up to 100 fps. A ...
Biology Products: